Sort   by:  
 Page size 

Importance

Easy-to-administer anti-SARS-CoV-2 treatments may be used to prevent progression from asymptomatic infection to symptomatic disease and to reduce viral carriage.

Objective

To evaluate the effect of combination subcutaneous casirivimab and imdevimab on progression from early...

Background

REGEN-COV (previously known as REGN-COV2), a combination of the monoclonal antibodies casirivimab and imdevimab, has been shown to markedly reduce the risk of hospitalization or death among high-risk persons with coronavirus disease 2019 (Covid-19). Whether subcutaneous REGEN-COV ...
Sort   by:  
 Page size